Human Psychopharmacology: Clinical and Experimental最新文献

{"title":"Issue Information","authors":"","doi":"10.1111/spc3.12608","DOIUrl":"https://doi.org/10.1111/spc3.12608","url":null,"abstract":"No abstract is available for this article.","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48838962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"‘Nico’—A lone voyager in Strange Seas","authors":"David S. Baldwin","doi":"10.1002/hup.2859","DOIUrl":"10.1002/hup.2859","url":null,"abstract":"<p>Christa Päffgen died in a corridor waiting for a hospital bed during the evening of July 18, 1988. She was 49 years old. Contemporaneous accounts state that she had cycled away from home in searing midday heat for distant downtown Ibiza hoping to buy hashish. She was found by strangers at a roadside that afternoon, unable to talk. A first hospital turned Christa away as a ‘vagrant junkie’; a second declined assessment because she had no health insurance; a third refused admission as she was an ‘old hippie’. Staff in a fourth hospital admitted her and ultimately diagnosed a cerebral haemorrhage, but could not insert a needle into her tired old veins: though she was undergoing methadone replacement therapy, she had previously been addicted to heroin for over 15 years.</p><p>Christa was more commonly known as ‘Nico’, and had been a model, actress, singer-songwriter and musician. She sang on four tracks of <i>The Velvet Underground and Nico (1967)</i>—including ‘Femme Fatale’ and ‘All Tomorrow's Parties'—with an austere, unornamented, deep contralto voice. Subsequent solo albums pushed against musical and emotional boundaries; and are considered unlistenable by some, ground-breaking by others. <i>The Marble Index</i> (1968),1 with its sorrowful plainsong, bleak swirling harmonium, and distorted viola gradually became regarded as an avant-garde classic. Nico associated with a <i>Who's Who</i> of male rock stars of the 1960/70s. Men were captivated by her beauty but threatened by her often scornful disdain: with notable exceptions, most treated her carelessly. In subsequent decades, she was no longer denigrated as a mere Muse or Mannequin, but instead valued as an exceptional though troubled musical visionary. But opiate addiction eroded her output remorselessly, and she spent most of her final years at the margins of the New Wave music scene, living precariously in Prestwich and Salford.</p><p>The relevance of the decline of ‘Nico’ to the concerns of psychopharmacologists and psychiatrists might seem somewhat tenuous: that is, before considering her experience of childhood trauma in wartime Germany, the recurring toll of abusive intimate relationships, and stigmatised attitudes towards drug addiction. The military call-up of her father contributed to her temporary placement in the largest orphanage in Europe, which was run according to mixed arch-Catholic and Nazi ideology. Her father subsequently died from war injuries before Christa could see him again. As a teenager she had to provide evidence at a court-martial, after being raped by a soldier of the post-war American occupying forces. As ‘Nico’, she was manipulated by a succession of men who exploited her allure, belittled her intelligence, and demeaned her artistry.</p><p>Nico showed the persistent detachment of recurrently traumatised individuals long before her preoccupying persistent concern about securing the next ‘fix’. As a single woman with only passing lovers and few possessions, and l","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.2859","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study","authors":"Chika Kubota,&nbsp;Toshiya Inada,&nbsp;Shih-Ku Lin,&nbsp;Ajit Avasthi,&nbsp;Kok Yoon Chee,&nbsp;Andi Jayalangkara Tanra,&nbsp;Shu-Yu Yang,&nbsp;Lian-Yu Chen,&nbsp;Mian-Yoon Chong,&nbsp;Adarsh Tripathi,&nbsp;Roy Abraham Kallivayalil,&nbsp;Sandeep Grover,&nbsp;Seon-Cheol Park,&nbsp;Takahiro A. Kato,&nbsp;Yu-Tao Xiang,&nbsp;Kang Sim,&nbsp;Margarita M. Maramis,&nbsp;Isa Multazam Noor,&nbsp;Chay-Hoon Tan,&nbsp;Norman Sartorius,&nbsp;Naotaka Shinfuku","doi":"10.1002/hup.2861","DOIUrl":"10.1002/hup.2861","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Drug-induced extrapyramidal syndrome (EPS) remains a major problem in clinical psychiatry. This study aimed to examine the factor structure of drug-induced extrapyramidal symptoms observed in patients with schizophrenia and assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The participants were 1478 patients with a diagnosis of schizophrenia whose EPS was assessed using the DIEPSS in India, Indonesia, Japan, Malaysia, and Taiwan in the 2016 REAP AP-4 study. The records of the participants were randomly divided into two subgroups: the first for exploratory factor analysis of the eight DIEPSS items, and the second for confirmatory factor analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The factor analysis identified three factors: F1 (gait and bradykinesia), F2 (muscle rigidity and tremor), and F3 (sialorrhea, akathisia, dystonia, and dyskinesia).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The results suggest that the eight individual items of the DIEPSS could be composed of three different mechanisms: acute parkinsonism observed during action (F1), acute parkinsonism observed at rest (F2), and central dopaminergic mechanisms with pathophysiology other than acute parkinsonism (F3).</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 2","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9482600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"J Guy Edwards, FRCPsych, FRCP, FRCGP (Hon), DPM, HonMFPH, Founding Editor of Human Psychopharmacology","authors":"Philip Cowen","doi":"10.1002/hup.2860","DOIUrl":"10.1002/hup.2860","url":null,"abstract":"&lt;p&gt;Guy Edwards dedicated his life to the clinical care of patients and was a full-time NHS consultant psychiatrist in Southampton until his retirement in 1993. This made his numerous achievements in psychopharmacology - carried out of necessity on top of his NHS work in his own time—particularly remarkable. In fact, coming from a working-class family in a Welsh mining village, Guy was the first member of his family to have full experience of secondary school, let alone a university education.&lt;/p&gt;&lt;p&gt;Admiration for the family GP prompted Guy to opt for medicine, and positive experiences of work with psychiatric patients as a medical student led him later to specialise in psychiatry in Manchester where he obtained his DPM in 1964. However, it was a chance encounter with Linford Rees that led Guy into the field of psychopharmacology. Rees knew that the famous American psychopharmacologist, Nathan Kline, was in London recruiting psychiatrists to assist in his drug development programme and arranged a meeting between them.&lt;/p&gt;&lt;p&gt;The meeting with Kline resulted in Guy spending three key years in the United States where he learned about laboratory and clinical aspects of psychopharmacology, the latter in collaboration with George Simpson involving clinical trials of antipsychotic drugs in the ‘Early Clinical Drug Assessment Unit (ECDU)’ at the Rockland Research Institute, New York. This was an exciting time for psychotropic drug development with the antipsychotic effects of chlorpromazine having been demonstrated just a few years earlier. At ECDU, Guy studied the clinical effects of several newer potential antipsychotic drugs, including thioxanthenes and butyrophenones. The experience gained here was important to Guy, when after returning to the UK, he carried out investigations of the therapeutic and adverse effects of other new antipsychotic agents such as remoxipride and sulpiride. Characteristically in this work he would devise his own protocols and be responsible personally for patient recruitment and clinical care.&lt;/p&gt;&lt;p&gt;Guy's contribution to the psychopharmacology of antidepressant drug treatment was particularly notable and showed his gift for collaboration with general medical and psychiatrist colleagues as well as his ability to identify issues important to clinicians and their patients. For example, recognising the problematic pro-convulsant effects of tricyclic antidepressants, Guy carried out studies with Michael Sedgwick, a Professor of Neurophysiology, looking at the effect on seizure threshold of alternative antidepressant agents such as mianserin and paroxetine. Similarly, with physician-pharmacologist Derek Waller, he compared the effects of antidepressants on cardiac conduction and assessed the consequences of lithium treatment on renal function.&lt;/p&gt;&lt;p&gt;Guy's combination of scientific insight and clinical acumen led him to be a frequent editorial writer for journals such as the British Medical Journal (BMJ). His judgement here was alway","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.2860","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial","authors":"Frederick Vinckenbosch,&nbsp;Gert Jan Lammers,&nbsp;Sebastiaan Overeem,&nbsp;Dan Chen,&nbsp;Grace Wang,&nbsp;Lawrence P. Carter,&nbsp;Kefei Zhou,&nbsp;Johannes G. Ramaekers,&nbsp;Annemiek Vermeeren","doi":"10.1002/hup.2858","DOIUrl":"10.1002/hup.2858","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving performance in participants with narcolepsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this randomised, double-blind, placebo-controlled, crossover study, driving performance during a 1 h on-road driving test was assessed at 2 and 6 h post-dose following 7 days of treatment with solriamfetol (150 mg/day for 3 days, followed by 300 mg/day for 4 days) or placebo. The primary endpoint was standard deviation of lateral position (SDLP) at 2 h post-dose.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 24 participants (54% male; mean age, 40 years); 22 had evaluable SDLP data. At 2 h post-dose, median SDLP was significantly lower (improved) with solriamfetol compared with placebo (19.08 vs. 20.46 cm [median difference, −1.9 cm], <i>p</i> = 0.002). Four participants on solriamfetol and 7 on placebo had incomplete driving tests. At 6 h post-dose, median SDLP was not statistically significantly different with solriamfetol compared with placebo (19.59 vs. 19.78 cm [median difference, −1.1 cm], <i>p</i> = 0.125). Three participants on solriamfetol and 10 on placebo had incomplete driving tests. Common adverse events (≥5%) included headache, decreased appetite, and somnolence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Solriamfetol 300 mg/day improved on-the-road driving performance, at 2 h post-administration in participants with narcolepsy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/c1/HUP-38-0.PMC10078175.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9266788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A diffusion tensor imaging study in schizophrenia patients with clozapine induced obsessive compulsive symptoms","authors":"Şule Bıçakcı Ay,&nbsp;Kader K. Oğuz,&nbsp;Elçin Özçelik Eroğlu,&nbsp;Arzu Ceylan Has,&nbsp;Aygün Ertuğrul","doi":"10.1002/hup.2857","DOIUrl":"10.1002/hup.2857","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of this study was to evaluate brain connectivity by diffusion tensor imaging (DTI) in schizophrenia patients with clozapine-induced obsessive compulsive symptoms (OCS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eighteen schizophrenia patients, nine of which had clozapine-induced OCS (Clz-OCS (+)), 9 without OCS (Clz-OCS (−)) and 9 healthy controls were included. Psychopathology was evaluated with Positive and Negative Syndrome Scale and Yale-Brown Obsession and Compulsion Scale in the patient groups. All groups were assesed with neurocognitive tests and DTI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Tract-Based Spatial Statistics based comparison of DTI revealed lower fractional anisotropy in the genu of corpus callosum (CC), right cingulum, left frontal white matter (WM) in the Clz-OCS (+) group, compared to controls. Fractional anisotropy was found to be lower in the bilateral occipital WM and higher in the bilateral medial temporal regions, anterior limb of internal capsule, cingulum, frontoparietal peripheral WM, right external capsule and genu of CC in Clz-OCS (+) patients compared to Clz-OCS (−).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>WM integrity in several pathways such as cortico-striato-thalamo-cortical circuitry and orbito-frontal tracts seems to be affected differently in patients with Clz-OCS (+). Different neuroplastic effects of clozapine leading to occurrence of OCS in a subgroup of patients is possible, and needs further evaluation by longitudinal follow-up studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10726051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.","authors":"Frederick Vinckenbosch, Jerryll Asin, Nicolaas de Vries, Patty E Vonk, Claire E H M Donjacour, Gert Jan Lammers, Sebastiaan Overeem, Hennie Janssen, Grace Wang, Dan Chen, Lawrence P Carter, Kefei Zhou, Annemiek Vermeeren, Johannes G Ramaekers","doi":"10.1002/hup.2845","DOIUrl":"10.1002/hup.2845","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA).</p><p><strong>Methods: </strong>Eligible participants were aged 21-75 years with OSA and EDS (Maintenance of Wakefulness Test mean sleep latency <30 minutes and Epworth Sleepiness Scale score ≥10). Participants were randomised 1:1 to solriamfetol (150 mg/day [3 days], then 300 mg/day [4 days]) or placebo for 7 days, before crossover to the other treatment paradigm. On Day 7 of each period, standardised on-road driving tests occurred (2 and 6 hours postdose). Standard deviation of lateral position (SDLP) was the primary endpoint.</p><p><strong>Results: </strong>Solriamfetol significantly reduced SDLP at 2 (n = 34; least squares mean difference, -1.1 cm; 95% CI, -1.85, -0.32; p = 0.006) and 6 hours postdose (n = 32; least squares mean difference, -0.8 cm; 95% CI, -1.58, -0.03; p = 0.043). Two hours postdose, 4 placebo-treated and 1 solriamfetol-treated participants had incomplete driving tests; 6 hours postdose, 7 and 3 participants, respectively, had incomplete tests. Common treatment-emergent adverse events included headache, nausea, and insomnia.</p><p><strong>Conclusions: </strong>Solriamfetol 300 mg/day significantly improved on-the-road driving performance in participants with EDS associated with OSA.</p>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 6","pages":"e2845"},"PeriodicalIF":1.8,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/08/HUP-37-e2845.PMC9788130.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10812193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose Vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression.","authors":"David T Field,&nbsp;Rebekah O Cracknell,&nbsp;Jessica R Eastwood,&nbsp;Peter Scarfe,&nbsp;Claire M Williams,&nbsp;Ying Zheng,&nbsp;Teresa Tavassoli","doi":"10.1002/hup.2852","DOIUrl":"https://doi.org/10.1002/hup.2852","url":null,"abstract":"<p><strong>Objective: </strong>Vitamins B6 and B12 are involved in metabolic processes that decrease neural excitation and increase inhibition. This double-blind study investigated the effects of supplementation for 1 month with a high-dose of B6 or B12, compared to placebo, on a range of behavioural outcome measures connected to the balance between neural inhibition and excitation.</p><p><strong>Methods: </strong>478 young adults were recruited over five linked phases. Self-reported anxiety (N = 265) and depression (N = 146) were assessed at baseline and after supplementation. Several sensory measures acted as assays of inhibitory function and were assessed post-supplementation only; these were surround suppression of visual contrast detection (N = 307), binocular rivalry reversal rate (N = 172), and a battery of tactile sensitivity tests (N = 180).</p><p><strong>Results: </strong>Vitamin B6 supplementation reduced self-reported anxiety and induced a trend towards reduced depression, as well as increased surround suppression of visual contrast detection, but did not reliably influence the other outcome measures. Vitamin B12 supplementation produced trends towards changes in anxiety and visual processing.</p><p><strong>Conclusions: </strong>Our results suggest that high-dose Vitamin B6 supplementation increases inhibitory GABAergic neural influences, which is consistent with its known role in the synthesis of GABA.</p>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 6","pages":"e2852"},"PeriodicalIF":1.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10445234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issue Information","authors":"","doi":"10.1002/hup.2799","DOIUrl":"https://doi.org/10.1002/hup.2799","url":null,"abstract":"No abstract is available for this article.","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44571751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic reviews of the acute effects of amphetamine on working memory and other cognitive performances in healthy individuals, with a focus on the potential influence of personality traits","authors":"Faiz M. Kassim","doi":"10.1002/hup.2856","DOIUrl":"10.1002/hup.2856","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This research aimed to systematically review the acute effects of amphetamine (AMP), a dopamine-releasing agent, on working memory (WM) and other cognitive performances. The investigation also aimed to review the impact of personality traits on the subjective and objective effects of AMP and possible links between personality traits and effects of AMP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Previous double-blind controlled studies assessing the main effects of AMP on WM and other cognitive performances in healthy volunteers were systematically reviewed. An electronic search was performed in the PUBMED and SCOPUS databases. Narrative reviews of the influence of personality traits on the subjective and objective effects of AMP were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nineteen WM studies were included in the current review. Seven studies found effects of AMP on spatial WM, but only one study found the effect of AMP on verbal WM. Thirty-seven independent studies on other aspects of cognitive performance were identified. Twenty-two reported effects of AMP on cognitive functions. Studies also showed that personality traits are associated with the subjective effects of AMP. However, few studies reported the impacts of personality traits on the objective (such as WM) effects of AMP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, findings indicate that AMP has mixed-effects on spatial WM and other cognitive functions, but it lacks effects on verbal WM. Although there are insufficient studies on objective measures, studies also indicated that the subjective effects of AMP administration are linked to between-person variations in personality traits.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/91/HUP-38-0.PMC10078276.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9267426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}